Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024)
Recursion Pharmaceuticals (RXRX) reported Acquisitions of -$277.1 million for Q4 2024, down 390387.32% on a YoY basis from N/an in Q1 2024, and down 390387.32% quarter-over-quarter from $71000.0 in Q4 2023.
Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024) Analysis & Trends
Recursion Pharmaceuticals has reported Acquisitions for 2 years, with the latest figure at -$277.1 million in Q4 2024.
- For the quarter ending Q4 2024, Acquisitions fell 390387.32% year-over-year to -$277.1 million; the trailing twelve-month figure through Dec 2024 stood at -$277.0 million (down 390287.32% YoY), and the FY2024 full-year result was -$277.1 million, down 14927.33% from the prior year.
- Acquisitions for Q4 2024 stood at -$277.1 million, down from $71000.0 in the prior quarter.
- The five-year high for Acquisitions was $71000.0 in Q4 2023, with the low at -$277.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -277.10 Mn |
| Dec 31, 2023 | 71,000.00 |